OTCMKTS:NEVPF

Abliva AB (publ) Stock Forecast, Price & News

$0.09

-0.02 (-15.59 %)

(As of 06/17/2021 09:37 AM ET)

Add

Compare

Today's Range

$0.09

▼

$0.09

50-Day Range

$0.07

▼

$0.12

52-Week Range

$0.06

▼

$0.15

Volume200 shs

Average Volume7,641 shs

Market Capitalization$25.27 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive NEVPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

About Abliva AB (publ)

Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Abliva AB (publ) (OTCMKTS:NEVPF) Short Interest Up 67.8% in May
May 30, 2021 | americanbankingnews.com

Abliva AB (publ) (OTCMKTS:NEVPF) Shares Up 35.6%
May 26, 2021 | americanbankingnews.com

BioInvent strengthens Investor Relations
November 28, 2020 | finanznachrichten.de

Venture Fund Manager Has $100 Million for Startups Run by Women
June 28, 2020 | finance.yahoo.com

Here's Why NeuroVive Pharmaceutical (STO:NVP) Must Use Its Cash Wisely
April 7, 2020 | finance.yahoo.com

NeuroVive Pharmaceutical AB reports Q4 results
February 19, 2020 | seekingalpha.com

Investors Who Bought NeuroVive Pharmaceutical (STO:NVP) Shares Five Years Ago Are Now Down 98%
February 4, 2020 | finance.yahoo.com

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
December 20, 2019 | markets.businessinsider.com

NeuroVive settles dispute with CicloMulsion AG
December 16, 2019 | seekingalpha.com

NeuroVive Announces Settlement in Dispute With CicloMulsion AG
December 16, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NEVPF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.neurovive.com
Phone46-4-627-562-20
Employees7
Year FoundedN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales2,526.84
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares269,673,000
Market Cap$25.27 million
Next Earnings Date6/23/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.50 out of 5 stars

Medical Sector

1657th out of 2,100 stocks

Pharmaceutical Preparations Industry

715th out of 831 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Abliva AB (publ).

2.5 Community Rank

Outperform Votes
Abliva AB (publ) has received 70 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Abliva AB (publ) has received 70 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Abliva AB (publ) has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Abliva AB (publ) and other stocks. Vote “Outperform” if you believe NEVPF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NEVPF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Abliva AB (publ) does not currently pay a dividend.
Dividend Growth
Abliva AB (publ) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abliva AB (publ) insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Abliva AB (publ) is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Abliva AB (publ) is -1.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Abliva AB (publ) (OTCMKTS:NEVPF) Frequently Asked Questions

What stocks does MarketBeat like better than Abliva AB (publ)?

Wall Street analysts have given Abliva AB (publ) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abliva AB (publ) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abliva AB (publ)?

Abliva AB (publ) saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 25,000 shares, an increase of 67.8% from the April 29th total of 14,900 shares. Based on an average daily volume of 30,900 shares, the short-interest ratio is presently 0.8 days.
View Abliva AB (publ)'s Short Interest.

When is Abliva AB (publ)'s next earnings date?

Abliva AB (publ) is scheduled to release its next quarterly earnings announcement on Wednesday, June 23rd 2021.
View our earnings forecast for Abliva AB (publ).

How has Abliva AB (publ)'s stock been impacted by Coronavirus?

Abliva AB (publ)'s stock was trading at $0.0796 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEVPF shares have increased by 17.7% and is now trading at $0.0937.
View which stocks have been most impacted by COVID-19.

Who are Abliva AB (publ)'s key executives?

Abliva AB (publ)'s management team includes the following people:

Dr. Ellen K. Donnelly, Chief Exec. Officer (Age 47)
Ms. Catharina Jz Johansson, Deputy CEO, CFO & VP of Investor Relations (Age 54)
Daniel Schale, Director of Communications
Dr. Magnus Hansson, Chief Medical Officer and VP of Preclinical & Clinical Devel. (Age 45)
Dr. Lars Vedin, Consultant

Who are some of Abliva AB (publ)'s key competitors?

Some companies that are related to Abliva AB (publ) include Evofem Biosciences (EVFM), Orgenesis (ORGS), Capricor Therapeutics (CAPR), Onconova Therapeutics (ONTX), Minerva Neurosciences (NERV), Eledon Pharmaceuticals (ELDN), Celsion (CLSN), Aileron Therapeutics (ALRN), Metacrine (MTCR), Vascular Biogenics (VBLT), Gain Therapeutics (GANX), Acasti Pharma (ACST), Helix BioPharma (HBPCF), LifeVantage (LFVN) and Rezolute (RZLTD).
View all of NEVPF's competitors.

What is Abliva AB (publ)'s stock symbol?

Abliva AB (publ) trades on the OTCMKTS under the ticker symbol "NEVPF."

How do I buy shares of Abliva AB (publ)?

Shares of NEVPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abliva AB (publ)'s stock price today?

One share of NEVPF stock can currently be purchased for approximately $0.09.

How much money does Abliva AB (publ) make?

Abliva AB (publ) has a market capitalization of $25.27 million and generates $10,000.00 in revenue each year.

How many employees does Abliva AB (publ) have?

Abliva AB (publ) employs 7 workers across the globe.

What is Abliva AB (publ)'s official website?

The official website for Abliva AB (publ) is www.neurovive.com.

Where are Abliva AB (publ)'s headquarters?

Abliva AB (publ) is headquartered at MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381.

How can I contact Abliva AB (publ)?

Abliva AB (publ)'s mailing address is MEDICON VILLAGE SCHEELEVAGEN 2, LUND V7, 22381. The company can be reached via phone at 46-4-627-562-20 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Abliva AB (publ) Stock Forecast, Price & News

About Abliva AB (publ)

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.5 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment